Insmed | INSM - Ebitda

Stock Price
146.65
Daily Change
1.55 1.07%
Monthly
29.91%
Yearly
104.19%
Q3 Forecast
143.90

Insmed reported $-297127000 in EBITDA for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 2.48B
Cash and Equivalent USD 1.28B
Cost of Sales USD 29.34M
Current Assets USD 2.08B
Current Liabilities USD 311.68M
Debt USD 564.1M
EBIT USD -253.88M
EBITDA USD -297.13M
Employees 1.27K
EPS Earnings Per Share USD -1.7
Equity Capital and Reserves USD 1.25B
Gross Profit on Sales USD 78.08M
Interest Expense on Debt USD 21.25M
Interest Income USD 0
Loan Capital USD 560.95M
Market Capitalization USD 21.64B
Net Income USD -321.69M
Operating Expenses USD 361.29M
Operating Profit USD -253.88M
Ordinary Share Capital USD 211.11M
Pre-Tax Profit USD -320.44M
Sales Revenues USD 107.4M
Selling and Administration Expenses USD 76.44M
Stock USD 107.61M
Trade Creditors USD 78.35M
Trade Debtors USD 55.03M

Ebitda Change Date
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Cytokinetics USD -153331000 16.67M Mar/2025
DBV Technologies USD -39036000 16.89M Jun/2025
Dynavax Technologies USD -21594000 22.03M Mar/2025
Gilead Sciences USD 3.4B 797M Jun/2025
Insmed USD -297127000 71.11M Jun/2025
Novartis USD 6.08B 739M Jun/2025
Regeneron Pharmaceuticals USD 1.66B 926.5M Jun/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Ultragenyx Pharmaceutical USD -91344000 35.09M Jun/2025
Vertex Pharmaceuticals USD 1.34B 556.6M Jun/2025